NVAX Q2 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$415M-2.1% YoY

Gross Profit

$369M88.9% margin

Operating Income

$161M38.7% margin

Net Income

$162M39.1% margin

EPS (Diluted)

$0.99

QoQ Revenue Growth

+342.7%

Cash Flow

Operating Cash Flow

$314M

Free Cash Flow

$311M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.3B

Stockholders' Equity

-$432M

Cash & Equivalents

$680M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$415M	$424M	-2.1%
Gross Profit	$369M	$369M	+0.2%
Operating Income	$161M	$55M	+190.3%
Net Income	$162M	$58M	+179.9%

Revenue Segments

Royalties and Other

$396M95%

Product

$20M5%

Geographic Segments

Rest of the World

$18M91%

North America

$2M8%

Europe

$169,0001%